The influence of mPEG-PCL and mPEG-PLGA on encapsulation efficiency and drug-loading of SN-38 NPs
Source abstract
Abstract
The influence of mPEG-PCL and mPEG-PLGA on encapsulation efficiency and drug-loading of nanoparticles was very important. SN-38 NPs were prepared from a series of diblock copolymers: mPEG1000-PLGA2000, mPEG2000-PCLs, mPEG5000-PCLs, mPEG2000-PLGAs, and mPEG5000-PLGAs by the thin film-hydration method. The prepared nanoparticles were characterized by morphology, size, encapsulation efficiency, drug-loading, and in vitro release behavior. This experiment suggested that the encapsulation efficiency and drug-loading of SN-38 NPs were attained the maximum values when the ratio of hydrophilic to hydrophobic block was between 1:2 and 1:3.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Hydrogels: synthesis, properties, applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia, China;
Department of Pharmacy, Institute of Clinical Pharmacology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
Funding
Natural Science Foundation of Ningxia Province
References (42)
Show source-provided references
1. 10.1016/S0927-7765(99)00058-210.1016/S0927-7765(99)00058-2 ↗
2. 10.1016/j.carres.2015.05.01110.1016/j.carres.2015.05.011 ↗
3. 10.3109/21691401.2015.102963310.3109/21691401.2015.1029633 ↗
4. 10.2478/v10007-009-0020-010.2478/v10007-009-0020-0 ↗
5. 10.1016/j.nano.2008.06.00210.1016/j.nano.2008.06.002 ↗
6. Chabner BA, Longo DL. 2001. Cancer Chemotherapy and Biotherapy: Principles and Practice. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins, pp. 579–646.
7. 10.3109/03639045.2011.57516210.3109/03639045.2011.575162 ↗
8. 10.1021/jm00100a02210.1021/jm00100a022 ↗
9. 10.3109/0363904090326198910.3109/03639040903261989 ↗
10. 10.1016/j.ijpharm.2010.12.02210.1016/j.ijpharm.2010.12.022 ↗
11. 10.1016/j.nano.2009.10.00310.1016/j.nano.2009.10.003 ↗
12. Ebrahimnejad P · PDA J Pharm Sci Technol · 2009 · 63 · 512
13. Fu XN · Chin New Drugs J · 2008 · 17 · 2132
14. 10.1088/0957-4484/23/20/20510110.1088/0957-4484/23/20/205101 ↗
15. Hsiang YH · J Biol Chem · 1985 · 260 · 1487310.1016/S0021-9258(17)38654-4 ↗
16. 10.1021/ma00073a01010.1021/ma00073a010 ↗
17. 10.1021/ma991634x10.1021/ma991634x ↗
18. 10.1080/1071754070182715410.1080/10717540701827154 ↗
19. 10.1016/S0168-3659(03)00239-610.1016/S0168-3659(03)00239-6 ↗
20. 10.1016/j.ijpharm.2009.06.00710.1016/j.ijpharm.2009.06.007 ↗
21. 10.2174/13816120677902626310.2174/138161206779026263 ↗
22. Pal A · Anticancer Res · 2005 · 25 · 331
23. 10.1021/bm800320z10.1021/bm800320z ↗
24. 10.3109/21691401.2015.110523910.3109/21691401.2015.1105239 ↗
25. 10.1248/bpb.17.66210.1248/bpb.17.662 ↗
26. 10.1016/j.jconrel.2004.06.00310.1016/j.jconrel.2004.06.003 ↗
27. 10.1021/bc034113u10.1021/bc034113u ↗
28. Slatter JG · Drug Metab Dispos · 1997 · 25 · 1157
29. 10.3109/21691401.2014.96531010.3109/21691401.2014.965310 ↗
30. Vangara KK · Anticancer Res · 2013 · 33 · 2425
31. Wadkins RM · Cancer Res · 1999 · 59 · 3424
32. 10.1039/C4RA04920A10.1039/C4RA04920A ↗
33. Wang Y · J Control Release · 2013 · 172 · e6710.1016/j.jconrel.2013.08.138 ↗
34. 10.1021/jm00393a01610.1021/jm00393a016 ↗
35. 10.1080/09205063.2014.91346710.1080/09205063.2014.913467 ↗
36. 10.1002/cmdc.20110045610.1002/cmdc.201100456 ↗
37. 10.1016/j.polymer.2007.09.02110.1016/j.polymer.2007.09.021 ↗
38. 10.1021/bm501519u10.1021/bm501519u ↗
39. 10.1016/j.ijpharm.2003.10.01510.1016/j.ijpharm.2003.10.015 ↗
40. Zhang S · Polym Materials Sci Eng · 2014 · 30 · 11
41. 10.1021/bc700333s10.1021/bc700333s ↗
42. Zheng D · West China J Pharm Sci · 2014 · 29 · 497